Keith W Pratz

19PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Feb 17, 2025
Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents.

Keith W Pratz, Harry P Erba

|Dec 23, 2024
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.

Keith W Pratz

|Feb 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.

Keith W Pratz, Brian A Jonas, Vinod Pullarkat

|Jun 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

Keith W Pratz, Mohamad Cherry, Jessica K Altman

|Jun 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.

Andrew H Matthews, Alexander E Perl, Selina M Luger

|Aug 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.

Daniel A Pollyea, Keith W Pratz, Andrew H Wei

Pageof 4

Frequent Collaborators

10 joint publications

Courtney DiNardo

7 joint publications

Brian A Jonas

7 joint publications

Christian Recher

4 joint publications

Vinod Pullarkat